BAYN.DE Stock Today: April 08 – Glyphosate Supreme Court Test Nears

Bayer stock today is in focus for German investors as legal and strategic drivers line up this month. With a U.S. glyphosate Supreme Court hearing set for 27 April and a $7.25B Missouri settlement at preliminary approval, litigation remains the near-term swing factor. Recent quotes around €39.27 and a one-year gain near 98% meet neutral momentum signals. Management’s push to lift pharma margins toward 30% by 2030 supports the long view, but leverage and cash flow constraints keep positioning disciplined for BAYN.DE into these catalysts.

Legal calendar: glyphosate test and Missouri settlement

On 27 April, the glyphosate Supreme Court preemption case could decide whether federal labels block many state failure-to-warn claims. A narrower path for lawsuits would likely reduce tail risk and lift the multiple. An adverse read keeps payouts and reserves in focus. For Bayer stock today, this binary legal step is the main volatility trigger in late April.

The $7.25B Missouri settlement has preliminary court approval and awaits final sign-off. Bayer generated about €2.98 in free cash flow per share TTM, implying roughly a €2.9B run rate against elevated leverage. Net debt to EBITDA stands near 3.17x, interest cover 2.75x, and the current ratio about 1.0. For Bayer stock today, liquidity planning and payout pacing remain central.

What today’s tape says: levels and signals

RSI at 47 sits neutral, while MACD’s positive histogram shows improving short-term momentum even as ADX near 19 signals no firm trend. For Bayer stock today, that mix argues for range trading until a catalyst hits. One-year performance is strong, yet On-Balance Volume is negative, suggesting rallies still need confirmation by sustained inflows.

Bollinger mid-band near €39.01 is a pivot, with €40.61 as first resistance and the Keltner upper band around €42.26 above that. ATR at 1.43 implies a typical daily swing near 3% to 4%. Price sits below the 50-day (€41.79) but above the 200-day (€33.29). A close over €40.61 can improve sentiment; otherwise €39 may act as support. See context from Welt.

Valuation, balance sheet, and cash flow

Market cap is about €38.6B, with debt to equity near 1.44 and net debt to EBITDA roughly 3.17x. Interest coverage stands around 2.75x, while cash per share is about €8.00 and the current ratio is close to 1.0. For Bayer stock today, these figures frame the room to handle litigation and invest in growth without stressing credit metrics.

Shares trade at about 0.85x sales and 1.49x book, with EV/EBITDA near 7.15. Free cash flow yield is roughly 7.6%, while the dividend yield sits around 0.28% after cuts. EPS is negative, so PE is not meaningful. For Bayer stock today, low multiples reflect legal risk but also create optionality if liabilities ease.

Pharma targets and medium-term upside

Management reaffirmed the goal to lift pharma margins toward 30% by 2030, supported by focus areas in oncology, cardiology, and women’s health. R&D intensity sits near 12.7% of revenue TTM. Execution on launches and costs can offset litigation noise over time. For Bayer stock today, credible progress on this path can re-rate earnings quality. Source: WirtschaftsWoche.

Key milestones include the 27 April Supreme Court hearing, potential updates on the Bayer settlement Missouri process, and earnings on 12 May 2026. Signals are mixed: our Company Rating on 7 April 2026 is Sell (C), while the Stock Grade is B with a Hold stance. For Bayer stock today, we prefer staged entries and tight risk control near €39.

Final Thoughts

For Bayer stock today, the trade-off is clear. Near term, the April 27 Supreme Court preemption test and the Missouri settlement path dominate direction. A positive legal turn could compress perceived liabilities and lift the multiple. A negative outcome would keep cash and leverage in the spotlight. Technically, we see a neutral setup: watch €39 as a pivot, €40.61 for a momentum break, and the 50-day near €41.79 as confirmation. Fundamentally, valuation is undemanding versus free cash flow, while pharma targets toward a 30% margin by 2030 frame longer-term upside. We would build exposure gradually, size positions modestly, and reassess after each catalyst.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.